Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1957 1
1958 1
1959 2
1962 4
1963 3
1965 6
1967 1
1969 2
1971 1
1972 3
1973 7
1974 2
1975 5
1976 9
1977 4
1978 3
1979 9
1980 6
1981 16
1982 20
1983 24
1984 21
1985 33
1986 66
1987 87
1988 49
1989 83
1990 78
1991 79
1992 115
1993 110
1994 132
1995 130
1996 143
1997 191
1998 232
1999 244
2000 276
2001 292
2002 362
2003 506
2004 644
2005 782
2006 890
2007 1038
2008 1291
2009 1550
2010 1784
2011 2184
2012 2469
2013 3018
2014 3493
2015 3963
2016 4098
2017 4432
2018 5122
2019 6093
2020 7067
2021 7902
2022 9403
2023 9448
2024 10791
2025 11871
2026 168

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92,413 results

Results by year

Filters applied: . Clear all
Page 1
mRNA vaccines: immunogenicity and quality characteristics.
Quan Y, Yang H, Li W, Li L. Quan Y, et al. Among authors: li w. J Nanobiotechnology. 2025 Nov 27. doi: 10.1186/s12951-025-03800-5. Online ahead of print. J Nanobiotechnology. 2025. PMID: 41310620 Free article. Review.
DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance.
Bi H, Li W, Ren L, Zhang H, Dong L, Chan A, Wang X, Yang L, Zhang X, Xue M, Qin H, Wu X, Hoeve-Scott JT, Zhang B, Li L, Wunderlich M, Mulloy JC, Rosen ST, Chen J, Li X, Chen CW, Su R. Bi H, et al. Among authors: li w. Nat Commun. 2025 Dec 2. doi: 10.1038/s41467-025-66966-4. Online ahead of print. Nat Commun. 2025. PMID: 41330929 Free article.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: li w. Lancet Oncol. 2025 Dec;26(12):1598-1611. doi: 10.1016/S1470-2045(25)00543-1. Lancet Oncol. 2025. PMID: 41308676 Clinical Trial.
92,413 results
You have reached the last available page of results. Please see the User Guide for more information.